ATRIAL FIBRILLATION IN HEMATO-ONCOLOGIC PATIENTS: EPIDEMIOLOGY, MECHANISMS, AND CLINICAL IMPLICATIONS

Background: Atrial fibrillation (AF) is a common cardiac arrhythmia that affects approximately 2% of the population. In the population of patients with hematological neoplasms, there is an increased risk of developing atrial fibrillation. Despite growing evidence linking AF with hematological malignancies, current research rarely differentiates individual malignancies, leaving significant gaps in understanding disease-specific mechanisms. Objective: The aim of this study is to demonstrate the correlation between an increased risk of atrial fibrillation in hemato-oncological patients, to present the mechanisms underlying the onset of AF in these patients, and to outline the challenges associated with arrhythmia management in this group of patients Materials and Methods: The article is based on scientific literature sourced from PubMed, SpringerLink and Google Scholar. Results: Patients with hematological malignancies have a markedly increased risk of developing atrial fibrillation compared to cancer-free patients. Multiple factors may explain this linking; for example, anemia, electrolyte disruption, cytokine-mediated atrial remodeling, radiation exposure, and side effects of various therapies, including anthracyclines, CAR-T, or tyrosine kinase-inhibitors. AF in this population is often complicated by higher rates of bleeding, thromboembolic events, and treatment interactions. Conclusions: Atrial fibrillation represents a growing clinical challenge in hematology and oncology, requiring individualized treatment and close multidisciplinary collaboration, especially between cardiologists and oncologists. Current data suggest the need for disease-specific testing, improved risk stratification models, and the identification of predictive biomarkers. A more profound understanding of the mechanisms linking AF and hematologic malignancies could ultimately improve prevention, diagnosis, and tailored therapeutic strategies.

Authors

Institutions

Publication Details

Journal
International Journal of Innovative Technologies in Social Science
Published
2025-12-19
DOI
https://doi.org/10.31435/ijitss.4(48).2025.4604
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ATRIAL FIBRILLATION IN HEMATO-ONCOLOGIC PATIENTS: EPIDEMIOLOGY, MECHANISMS, AND CLINICAL IMPLICATIONS

Szymon Stupnicki, Mateusz Szot, Natalia Kwaśniewska, Aleksandra Oparcik et al.
International Journal of Innovative Technologies in Social Science
Atrial Fibrillation Management and Outcomes
article

ATRIAL FIBRILLATION IN HEMATO-ONCOLOGIC PATIENTS: EPIDEMIOLOGY, MECHANISMS, AND CLINICAL IMPLICATIONS

Szymon Stupnicki, Mateusz Szot, Natalia Kwaśniewska, Aleksandra Oparcik, Jakub Tarczykowski, Mikołaj Zakryś, Katarzyna Anna Zakryś, Michał Woźniak
article en

Abstract

Background: Atrial fibrillation (AF) is a common cardiac arrhythmia that affects approximately 2% of the population. In the population of patients with hematological neoplasms, there is an increased risk of developing atrial fibrillation. Despite growing evidence linking AF with hematological malignancies, current research rarely differentiates individual malignancies, leaving significant gaps in understanding disease-specific mechanisms. Objective: The aim of this study is to demonstrate the correlation between an increased risk of atrial fibrillation in hemato-oncological patients, to present the mechanisms underlying the onset of AF in these patients, and to outline the challenges associated with arrhythmia management in this group of patients Materials and Methods: The article is based on scientific literature sourced from PubMed, SpringerLink and Google Scholar. Results: Patients with hematological malignancies have a markedly increased risk of developing atrial fibrillation compared to cancer-free patients. Multiple factors may explain this linking; for example, anemia, electrolyte disruption, cytokine-mediated atrial remodeling, radiation exposure, and side effects of various therapies, including anthracyclines, CAR-T, or tyrosine kinase-inhibitors. AF in this population is often complicated by higher rates of bleeding, thromboembolic events, and treatment interactions. Conclusions: Atrial fibrillation represents a growing clinical challenge in hematology and oncology, requiring individualized treatment and close multidisciplinary collaboration, especially between cardiologists and oncologists. Current data suggest the need for disease-specific testing, improved risk stratification models, and the identification of predictive biomarkers. A more profound understanding of the mechanisms linking AF and hematologic malignancies could ultimately improve prevention, diagnosis, and tailored therapeutic strategies.

International Journal of Innovative Technologies in Social ScienceVol. 3(4(48))
Poznan University of Medical Sciences (PL), National Academy of Medicine (US), Postgraduate School of Molecular Medicine (PL), Wyższa Szkoła Humanistyczna (PL)
Good health and well-being
Openalex Percentile: Top 29%
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.